About the Editors
Chief Editor: Peter Kirkpatrick, PhD, Springer Nature, UK ORCID
Peter Kirkpatrick studied for a BA at the University of Cambridge, UK, specializing in chemistry. He stayed in Cambridge for his PhD, investigating the biosynthesis and mode of action of vancomycin-group antibiotics in the group of Dudley Williams. Following post-doctoral research in this group, he joined the launch team of Nature Reviews in 2000. He joined the launch team of Nature Reviews Drug Discovery as Associate Editor in 2001, and became Chief Editor in 2004. He is a member of the Board of Trustees for the charity Antibiotic Research UK. Peter is based in London, UK.
Senior Editor: Sarah Crunkhorn, PhD, Springer Nature, USA ORCID
Sarah Crunkhorn studied for her BSc at the University of Sheffield where she obtained a first in pharmacology. Following her doctoral research in molecular toxicology at the University of Surrey in collaboration with GlaxoSmithKline, where she investigated mechanisms mediating xenobiotic-induced liver growth, she moved to the Joslin Diabetes Centre, Harvard Medical School, Boston, USA, for her postdoctoral research. There she carried out studies aimed to identify novel molecular mechanisms of thiazolidinedione action in humans, and explored the mechanistic role of obesity and overnutrition in modulating muscle gene expression important in the pathophysiology of insulin resistance and type 2 diabetes. She joined Nature Reviews Drug Discovery as an Associate Editor in May 2007. Sarah is based in Boston, USA.
Senior Editor: M. Teresa Villanueva, PhD, Springer Nature, UK ORCID
M. Teresa Villanueva graduated with a degree in Pharmacy from the University of Granada, Spain. She obtained her PhD in Joaquín Arribas' laboratory at the Vall d'Hebrón Institute of Oncology in Barcelona, where she studied the role of the metalloproteinase TACE in breast cancer. She continued her research work as a postdoctoral fellow in the Oncological Sciences department at Mount Sinai Hospital, New York, investigating the effects of WNT signaling inhibition in breast and ovarian cancer initiation. She joined the Nature Reviews department in 2010, and after working for Nature Reviews Clinical Oncology and Nature Reviews Cancer, she joined Nature Reviews Drug Discovery as a Senior Editor in March 2017. Teresa is based in London, UK.
Senior Editor: Alex Eccleston, PhD, Springer Nature, UK
Alex Eccleston studied for a BSc in molecular biology and biochemistry at the University of Durham and obtained a PhD at the ICRF (now Cancer Research UK). She then carried out postdoctoral research on RAS signalling pathways at Onyx Pharmaceuticals, California, USA, before moving into science publishing. Following editorial positions at Current Biology and Trends in Cell Biology, she worked as a Senior Editor at Nature for nearly 20 years. Alex started at Nature Reviews Drug Discovery in 2022 and is based in London, UK.
Senior Editor (News): Katie Kingwell, MA, Springer Nature, UK
Katie Kingwell obtained a BA in physiological sciences from the University of Oxford, UK, and undertook a year of postgraduate research in the Pharmacology Department of the University of Cambridge, UK. She joined the Nature Reviews department in 2008 as Locum Copy Editor of Nature Reviews Drug Discovery, before becoming Locum Assistant Editor of that journal and Nature Reviews Neuroscience. She then worked on Nature Reviews Neurology as Associate Editor and Senior Editor, with a special interest in Alzheimer's disease and multiple sclerosis. She assumed her current role in 2014. Katie is based in London, UK.
The Reviews Cross-Journal Editorial Team works across the Nature Reviews portfolio, as the need arises, handling content in the life, clinical, physical, and social sciences.
